In a report published by Wedbush, its initiating coverage of Gentium S.p.A. GENT with an Outperform rating and $16 fair value.
Wedbush said that Gentium, S.p.A, is a cash-flow positive biotechnology company focused on using defibrotide to treat and prevent Veno-Occlusive Disease (VOD), a Stem Cell Transplant (SCT) complication with a high mortality and morbidity rate. “We are initiating coverage with a OUTPERFORM rating and a $16 fair value. We derive our fair value estimate by applying a 6x multiple to 2012 defibrotide sales, combined with an 15X multiple on 2012 US royalty income, discounted 25% annually, as Gentium is already essentially a commercial company. We use the current exchange rate of $1.38: €1.”
Gentium S.p.A.closed yesterday at $9.15.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.